Department of Defense Vision, Translational Research Award
The Department of Defense is offering the FY19 VRP Translational Research Award to support research that advances the prevention, diagnosis, mitigation, and treatment of eye injury or visual dysfunction related to military-relevant trauma. Successful applicants will focus on translating discoveries into clinical applications, aiming to develop new drugs, devices, or clinical practice guidelines ready for testing in clinical trials. Collaboration with FDA regulatory experts is encouraged. The grant also allows for expanding previously funded impactful research projects. Deadline for submission is December 6, 2019.
Science and Technology and other Research and Development
Category Explanation:
–
Expected Number of Awards:
3
Assistance Listings:
12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement:
No
Version:
Synopsis 1
Posted Date:
May 24, 2019
Last Updated Date:
May 24, 2019
Original Closing Date for Applications:
Dec 06, 2019
Current Closing Date for Applications:
Dec 06, 2019
Archive Date:
Jan 05, 2020
Estimated Total Program Funding:
$3,600,000
Award Ceiling:
–
Award Floor:
–
Eligibility
Eligible Applicants:
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
–
Additional Information
Agency Name:
Dept. of the Army — USAMRAA
Description:
The FY19 VRP Translational Research Award is intended to
support translational research that moves promising discoveries into clinical
applications that will advance the prevention, diagnosis, mitigation, and/or
treatment of eye injury or visual dysfunction associated with military-relevant
trauma.
Successful applications to the FY19 VRP TRA should establish
a clear path to transform a discovery into new drugs, devices, or clinical
practice guidelines that are ready for definitive testing in clinical trials.
It is expected that an Investigational New Drug (IND)/Investigational Device
Exemption (IDE) application will be submitted during or by the end of the
period of performance. Applicants are strongly encouraged to include at
least one collaborator with expertise in the U.S. Food and Drug Administration
(FDA) regulatory approval process on the investigative team.
The National Cancer Institute Translational Research Working
Group (TRWG) conceptualized translational research as a set of developmental
pathways leading to various clinical goals (http://clincancerres.aacrjournals.org/content/14/18/5664).
Applicants may consult the TRWG pathways for guidance on the design of
translational research projects.
Expansion Option: Expansion of a highly impactful
research project that was previously funded through a VRP funding opportunity
is encouraged but not required. Applicants choosing the Expansion Option must
submit an Outcomes Statement (Attachment 6), which is a summary of the
research funded through the original VRP award and a description of the research
results, accomplishments, and outcomes from that award. Applicants should
explain how these results, accomplishments, and outcomes relate to the FY19 VRP
TRA application.
Link to Additional Information:
–
Grantor Contact Information:
If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org Email:help@eBRAP.org
Version History
Version
Modification Description
Updated Date
Related Documents
Folder 316376 Full Announcement-FY19 VRP TRA -> VRP FY19 IND Documentation Form.pdf
Folder 316376 Full Announcement-FY19 VRP TRA -> VRP_FY19_TRA_GG.PDF
Packages
Agency Contact Information:
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org
